Summit Therapeutics Inc. (SMMT) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | Payments of Dividends |
| Net income · 12 months | -856.09M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-856.09M | (m) |
| 2026-03-31 | (m) | $-1.21B | (m) |
| 2025-12-31 | (m) | $-1.08B | (m) |
| 2025-09-30 | (m) | $-921.62M | (m) |
| 2025-06-30 | (m) | $-746.08M | (m) |
| 2025-03-31 | (m) | $-240.75M | (m) |
| 2024-12-31 | (m) | $-221.31M | (m) |
| 2024-09-30 | (m) | $-196.68M | (m) |
| 2024-06-30 | (m) | $-161.69M | (m) |
| 2024-03-31 | (m) | $-116.03M | (m) |
| 2023-12-31 | (m) | $-614.93M | (m) |
| 2023-09-30 | (m) | $-597.59M | (m) |
| 2023-06-30 | (m) | $-597.71M | (m) |
| 2023-03-31 | (m) | $-599.76M | (m) |
| 2022-12-31 | (m) | $-78.78M | (m) |
| 2022-09-30 | (m) | $-86.65M | (m) |
| 2022-06-30 | (m) | $-84.87M | (m) |
| 2022-03-31 | (m) | $-92.51M | (m) |
| 2021-12-31 | (m) | $-88.60M | (m) |
| 2021-09-30 | (m) | $-75.04M | (m) |
| 2021-06-30 | (m) | $-73.19M | (m) |
| 2021-03-31 | (m) | $-64.05M | (m) |
| 2020-12-31 | $0.00 | $-52.70M | 0.00% |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-01-31 | $0.00 | $9.90M | 0.00% |
| 2018-01-31 | $0.00 | $-26.35M | 0.00% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |